Latest news with #chronicwounds
Associated Press
16-06-2025
- Business
- Associated Press
SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers
CAMBRIDGE, England--(BUSINESS WIRE)--Jun 16, 2025-- SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational Aurase Wound Gel (AWG), in the treatment of patients with calciphylaxis ulcers. The designation recognises the potential of AWG in the treatment of this new indication, widening its application in the healing of chronic wounds whilst expediting the speed at which the new therapy could be available to patients. Calciphylaxis is a rare but serious condition involving the calcification of small blood vessels in the fat and skin tissues. It leads to blood clots, painful skin ulcers, and can progress to severe infections and sepsis. Although most commonly associated with end-stage renal disease, the condition can also occur in individuals with normal kidney function. With limited treatment options and a high one-year mortality rate 123, AWG offers an alternative debridement solution that potentially reduces the risk of infection and sepsis, opening up treatment options for patients previously considered too fragile to receive the current standard of care and improving outcomes in this vulnerable population. AWG is a hydrogel releasing Tarumase, a recombinant enzyme originally isolated from medical maggots, which selectively targets fibrin, collagen and elastin in wounds to promote healing through debridement and wound bed preparation. It is currently in Phase II Clinical trials for the treatment of venous leg ulcers, having established proof-of-concept, a strong safety profile and pain-free application 4. David Fairlamb, Chief Development Officer at SolasCure said:'Given the unmet medical need and the poor outcomes for patients with calciphylaxis, the FDA's granting Fast Track Designation is a significant milestone. Not only does it reflect the promise of Aurase Wound Gel in the treatment of calciphylaxis ulcers, but it also adds a new indication, increasing its potential to help more patients, therefore opening up an even larger target market for SolasCure.' For more information about SolasCure, please visit: References View source version on CONTACT: Media: Sarah Jeffery Email:[email protected] KEYWORD: UNITED KINGDOM EUROPE INDUSTRY KEYWORD: HEALTH FDA CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: SolasCure Copyright Business Wire 2025. PUB: 06/16/2025 06:23 AM/DISC: 06/16/2025 06:22 AM
BBC News
28-05-2025
- Business
- BBC News
New £48m wound research centre to open in Hull
A university has been awarded £48m to build a world-leading centre for research into University of Hull has been given funding to build the Wound Innovation Centre, which it says will research ways to improve life for people with chronic NHS spends about £8.3bn a year on wound care - more than obesity and cancer, according to the university. Mat Hardman, professor of wound healing at Hull York Medical School and director of the new centre, said: "Current treatments for wounds are woefully inadequate and we now have an opportunity to change this." The centre will be based at the University of Hull and upgrades are planned at Castle Hill Hospital to provide premium facilities for early-stage wound treatment Burns, 66, from Withernsea, has an unhealed ulcer he got from a leg wound after tripping over a child's go-kart four years Burns said: "There have been times I've been walking around all day and my pain is at a nine or 10 and there's nothing I can do to make it feel better. I can't sleep and it is mentally very damaging."Mr Burns said current treatments do not work but he feels "more able to cope" and "more supported" after taking part in clinical trials with the University of Hull's vascular team."It is so important that these trials and research into new developments in wound care continue," he Burns added: "I believe this new centre will be a real asset to the region and will pioneer new wound care treatment that will bring relief to all those who are suffering. "It will really change lives."The research hub is due to open at the end of the year, a spokesperson for the university said. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
